All In Biotech

Drug Trial Radar · NCT01449513

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

A Phase 1, Two-stage, Single-centre, Open Label, Within- and Between-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Subjects With Actinic Keratosis on the Upper Extrem-ity. A Single-arm First Stage Followed by a Two-arm, Parallel Group, Randomized, Placebo (Vehicle) -Controlled Second Stage

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Sep 2011

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Oct 10, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol mebutateDrug

    0.05% Ingenol mebutate Gel once daily for 2 consecutive days

  • Placebo GelDrug

    Gel vehicle of PEP005

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Degree of InfiltrationTime frame: Baseline to Day 2
  2. Change in Degree of InfiltrationTime frame: Baseline to Day 2
  3. Change in Degree of InfiltrationTime frame: Baseline to Day 2
  4. Change in Degree of InfiltrationTime frame: Baseline to Day 3
  5. Change in Degree of InfiltrationTime frame: Baseline to Day 3
  6. Change in Degree of InfiltrationTime frame: Baseline to Day 3
  7. Change in Degree of InfiltrationTime frame: Baseline to Day 8
  8. Change in Degree of InfiltrationTime frame: Baseline to Day 8
  9. Change in Degree of InfiltrationTime frame: Baseline to Day 8
  10. Change in Degree of InfiltrationTime frame: Baseline to Day 57
  11. Change in Degree of InfiltrationTime frame: Baseline to Day 57
  12. Change in Degree of InfiltrationTime frame: Baseline to Day 57
  13. Change in Degree of NecrosisTime frame: Baseline to Day 2
  14. Change in Degree of NecrosisTime frame: Baseline to Day 2
  15. Change in Degree of NecrosisTime frame: Baseline to Day 2
  16. Change in Degree of NecrosisTime frame: Baseline to Day 3
  17. Change in Degree of NecrosisTime frame: Baseline to Day 3
  18. Change in Degree of NecrosisTime frame: Baseline to Day 3
  19. Change in Degree of NecrosisTime frame: Baseline to Day 8
  20. Change in Degree of NecrosisTime frame: Baseline to Day 8
  21. Change in Degree of NecrosisTime frame: Baseline to Day 8
  22. Change in Degree of NecrosisTime frame: Baseline to Day 57
  23. Change in Degree of NecrosisTime frame: Baseline to Day 57
  24. Change in Degree of NecrosisTime frame: Baseline to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.